Literature DB >> 21550968

Non-Hodgkin's lymphomas.

Andrew D Zelenetz1, Jeremy S Abramson, Ranjana H Advani, C Babis Andreadis, Nancy Bartlett, Naresh Bellam, John C Byrd, Myron S Czuczman, Luis E Fayad, Martha J Glenn, Jon P Gockerman, Leo I Gordon, Nancy Lee Harris, Richard T Hoppe, Steven M Horwitz, Christopher R Kelsey, Youn H Kim, Ann S LaCasce, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Barbara Pro, Nashitha Reddy, Lubomir Sokol, Lode J Swinnen, Christina Tsien, Julie M Vose, William G Wierda, Joachim Yahalom, Nadeem Zafar.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21550968     DOI： 10.6004/jnccn.2011.0046

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


× No keyword cloud information.
  21 in total

Review 1.  Hepatitis B virus management to prevent reactivation after chemotherapy: a review.

Authors:  Jessica P Hwang; John M Vierling; Andrew D Zelenetz; Susan C Lackey; Rohit Loomba
Journal:  Support Care Cancer       Date:  2012-08-30       Impact factor: 3.603

2.  Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections.

Authors:  Carla Casulo; Jocelyn Maragulia; Andrew D Zelenetz
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-12-29

3.  Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.

Authors:  Carla Casulo; Michelle Byrtek; Keith L Dawson; Xiaolei Zhou; Charles M Farber; Christopher R Flowers; John D Hainsworth; Matthew J Maurer; James R Cerhan; Brian K Link; Andrew D Zelenetz; Jonathan W Friedberg
Journal:  J Clin Oncol       Date:  2015-06-29       Impact factor: 44.544

4.  Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study.

Authors:  Jonathan W Friedberg; Michelle Byrtek; Brian K Link; Christopher Flowers; Michael Taylor; John Hainsworth; James R Cerhan; Andrew D Zelenetz; Jamie Hirata; Thomas P Miller
Journal:  J Clin Oncol       Date:  2012-08-20       Impact factor: 44.544

5.  Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource.

Authors:  Brian K Link; Matthew J Maurer; Grzegorz S Nowakowski; Stephen M Ansell; William R Macon; Sergei I Syrbu; Susan L Slager; Carrie A Thompson; David J Inwards; Patrick B Johnston; Joseph P Colgan; Thomas E Witzig; Thomas M Habermann; James R Cerhan
Journal:  J Clin Oncol       Date:  2013-07-29       Impact factor: 44.544

6.  A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab.

Authors:  Oliver W Press; Joseph M Unger; Lisa M Rimsza; Jonathan W Friedberg; Michael LeBlanc; Myron S Czuczman; Mark Kaminski; Rita M Braziel; Catherine Spier; Ajay K Gopal; David G Maloney; Bruce D Cheson; Shaker R Dakhil; Thomas P Miller; Richard I Fisher
Journal:  Clin Cancer Res       Date:  2013-10-15       Impact factor: 12.531

7.  Diagnostic value of medical thoracoscopy in malignant pleural effusion induced by non-Hodgkin's lymphoma.

Authors:  Zhen Wang; Yan-Bing Wu; Li-Li Xu; Mu-Lan Jin; Xiao-Li Diao; Xiao-Juan Wang; Zhao-Hui Tong; Huan-Zhong Shi
Journal:  Oncol Lett       Date:  2017-10-19       Impact factor: 2.967

8.  Has the time to come leave the "watch-and-wait" strategy in newly diagnosed asymptomatic follicular lymphoma patients?

Authors:  Antonio Rueda; María Casanova; Maximino Redondo; Elisabeth Pérez-Ruiz; Angeles Medina-Pérez
Journal:  BMC Cancer       Date:  2012-05-31       Impact factor: 4.430

9.  Apoptosis inhibition or inflammation: the role of NAIP protein expression in Hodgkin and non-Hodgkin lymphomas compared to non-neoplastic lymph node.

Authors:  Safoura Mazrouei; Amin Ziaei; Amir Pouya Tanhaee; Kianoosh Keyhanian; Mahdad Esmaeili; Azar Baradaran; Mansoor Salehi
Journal:  J Inflamm (Lond)       Date:  2012-02-23       Impact factor: 4.981

10.  Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial.

Authors:  Pier Luigi Zinzani; Nuriet K Khuageva; Huaqing Wang; Bernardo Garicochea; Jan Walewski; Achiel Van Hoof; Pierre Soubeyran; Dolores Caballero; Rena Buckstein; Dixie-Lee Esseltine; Panteli Theocharous; Christopher Enny; Eugene Zhu; Yusri A Elsayed; Bertrand Coiffier
Journal:  J Hematol Oncol       Date:  2012-10-22       Impact factor: 17.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.